Proliferative myositis: expanding the differential diagnosis of a soft tissue mass in infancy.

Division of Pediatric Orthopaedics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA.
Skeletal Radiology (Impact Factor: 1.74). 09/2011; 40(12):1623-7. DOI: 10.1007/s00256-011-1274-4
Source: PubMed

ABSTRACT Proliferative myositis, a pseudosarcomatous lesion of skeletal muscle, is quite rare in the pediatric population. While benign, it is not always recognized as such, and may be treated with an extensive resection that can result in permanent disfigurement. We report a case of an infant with the diagnosis of proliferative myositis, who to our knowledge is the youngest patient to be evaluated with magnetic resonance imaging (MRI). Although the MRI findings are non-specific, we highlight the importance of considering proliferative myositis in the differential diagnosis of a soft tissue mass, which ultimately might prevent an overly aggressive resection in a child.

  • [Show abstract] [Hide abstract]
    ABSTRACT: This review updates recent trends in the classification of the juvenile idiopathic inflammatory myopathies (JIIM) and the emerging standard of treatment of the most common form of JIIM, juvenile dermatomyositis. The JIIM are rare, heterogeneous autoimmune diseases that share chronic muscle inflammation and weakness. A growing spectrum of clinicopathologic groups and serologic phenotypes defined by the presence of myositis autoantibodies are now recognized, each with differing demographics, clinical manifestations, laboratory findings, and prognoses. Although daily oral corticosteroids remain the backbone of treatment, disease-modifying anti-rheumatic drugs are almost always used adjunctively and biologic therapies may benefit patients with recalcitrant disease.
    Rheumatic diseases clinics of North America 11/2013; 39(4):877-904. · 2.59 Impact Factor